{"id":308016,"date":"2024-03-08T10:41:41","date_gmt":"2024-03-08T16:41:41","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=308016"},"modified":"2024-03-20T14:09:59","modified_gmt":"2024-03-20T19:09:59","slug":"emergency-room-visits-abortion-pill-tens-thouands","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/emergency-room-visits-abortion-pill-tens-thouands\/","title":{"rendered":"Emergency room visits from abortion pill estimated in the tens of thousands"},"content":{"rendered":"
<\/div>

UPDATE, 3\/20\/24:<\/strong> In March, the Guttmacher Institute published actual abortion pill totals for 2023, which were slightly higher than what was estimated here. Those updated numbers can be seen at Live Action News here<\/a>.<\/p>\n

3\/8\/24:<\/strong> Abortion pill-related emergency room visits are estimated to be in the tens of thousands, based on published percentages for ER visits on the drug’s 2023 label<\/a>. The label, according to plaintiffs in an abortion pill lawsuit soon to be heard by the U.S. Supreme Court, also allegedly shows that \u201croughly one in 25 women who take mifepristone will end up in the emergency room.\u201d<\/p>\n

In addition, according to the drug’s medication guide, it is estimated that in 2023, between 11,000 and 39,000 women who took the abortion pill potentially needed “a surgical procedure because the pregnancy did not completely pass from the uterus or to stop bleeding.“<\/em><\/p>\n

Currently there are no federal requirements that abortion pill complications or ‘adverse events’ must be reported, other than known abortion pill-related deaths.<\/p>\n

‘One in 25\u2019 Abortion Pill Clients Could End Up in ER<\/strong><\/p>\n

In its brief<\/a>, filed in the Alliance for Hippocratic Medicine (AHM) v. Food and Drug Administration (FDA)<\/em> case being heard before the United States Supreme Court this month, AHM wrote<\/a>,\u00a0\u201cFDA has long recognized that emergency care is essential to handle abortion-drug complications; the agency\u2019s own numbers say that roughly one in 25 women who take mifepristone will end up in the emergency room; and Respondent doctors have testified to routinely treating women suffering abortion drug harm,\u201d the AHM brief claimed.<\/p>\n

\u201cFactor in that hundreds of thousands of women take abortion drugs each year in the United States, and that FDA\u2019s own data indicates that tens of thousands of them go to the emergency room, and Respondents easily establish a \u2018substantial risk\u2019 that these harms \u2018will occur\u2019 again.\u201d<\/p>\n

To justify that statistic, AHM pointed out how the FDA’s own 2023 mifepristone label<\/a> in table 2 (Serious Adverse Reactions Reported in Women Following Administration of Mifepristone [oral] and Misoprostol [buccal] in U.S. and Non-U.S. Clinical Studies) acknowledges that \u201c2.9 to 4.6 percent of women who take abortion drugs end up in the emergency room.\u201d<\/p>\n

\"Mifepristone

Mifepristone Jan 2023 label shows percentage of women taking abortion pill visit ER<\/p><\/div>\n

The data also is similar to findings from a previously<\/a> documented\u00a0Gynuity Health Projects (GHP)<\/a> telabortion study which found that six percent (6%) of participants (70 out of 1,157) faced complications from the abortion pill which resulted in ER visits or urgent care<\/a> visits. Gynuity is a pro-abortion group, conducting clinical trials on the abortion pill and funded<\/a>\u00a0by organizations with deep historic ties to the American\u00a0eugenics<\/a> movement.<\/p>\n

Black Box Warning and Medication Guide\u00a0<\/strong><\/p>\n

\u201cFDA\u2019s current label for mifepristone continues to require a Black Box warning because the drug can cause \u2018[s]erious and sometimes fatal infections and bleeding\u2019\u2026 It also directs women to emergency rooms if one of many adverse complications arise,\u201d AHM wrote in the brief.<\/p>\n

The doctors added:<\/p>\n

On that label, FDA estimates that 2.9 to 4.6 percent of women will visit the emergency room after taking mifepristone\u2026 And FDA\u2019s\u00a0medication guide<\/a>\u00a0acknowledges that as many as 7 percent of women will need surgery after taking mifepristone \u2018to stop bleeding\u2019 or to complete the abortion\u2026<\/em><\/p>\n

The label also warns that a prescriber must \u2018[e]xclude [ectopic pregnancy] before treatment,\u2019\u2026\u2019because some of the expected symptoms experienced with a medical abortion (abdominal pain, uterine bleeding) may be similar to those of a ruptured ectopic pregnancy.\u2019<\/em><\/p>\n

\n
\"Abortion

Abortion pill Black Box warning and medication guide suggests sending women to ER<\/p><\/div>\n<\/div>\n

This number was reiterated in a separate amicus brief filed by the Family Research Council and Martha Shuping, M.D., which stated in part, “The current mifepristone label states that 2.9\u20134.6% of women will require an emergency room visit. This mirrors another established source. According to a health education page on the University of California San Francisco (UCSF) website<\/a>, ‘[a]bout 3 to 5% of patients need an additional aspiration procedure due to ongoing pregnancy, prolonged or excessive bleeding, or preference.’\u201d<\/p>\n

Tens of Thousands of Abortion Pill Clients Potentially Present to ER<\/strong><\/p>\n

Abortions by pill now\u00a0make up<\/a>\u00a0the\u00a0majority<\/a> of all abortions committed in the United States \u2014 53% in 2020 alone, according to Planned Parenthood’s former “research affiliate” the Guttmacher Institute.<\/p>\n

2020<\/u>:<\/p>\n